The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index; 10 of the 122 sources its claims cite were checked for support.
The clinical symptoms of Parkinson's disease.
Open accessAbstract
A review describing both motor and non-motor clinical features of Parkinson's disease in the context of disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 of 122 cited sources checked · 8 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“Depression and anxiety may also occur long before the diagnosis is made (Chen et al. 2013).”
What the sources say
- Supportedcites Chen et al. 2013 source
The Introduction says that accumulating evidence suggests depression and anxiety may occur well before the motor dysfunction used to diagnose Parkinson’s disease. Its table also lists studies assessing both symptoms years before PD diagnosis. This supports the citing sentence’s qualified wording, “may.” (LLM, conf=0.94)
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These may start as early as 10 or more years before the diagnosis (Schrag et al. 2015)”
What the sources say
- Supportedcites Schrag et al. 2015 source
The Results (p. 5) report that constipation, a non-motor symptom, was more common in people later diagnosed with Parkinson’s disease at 10 years before diagnosis. The Discussion (p. 6) also reports an association between erectile dysfunction and a Parkinson’s diagnosis more than 10 years later, supporting the claim’s qualified wording. (LLM, conf=0.91)
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although obstructive sleep apnoea, where breathing stops intermittently during sleep, is well known in PD (Monderer and Thorpy 2008), not all studies have shown increased prevalence among patients (Zeng et al. 2013).”
What the sources say
- Supportedcites Zeng et al. 2013 source
The Discussion says many studies found similar rates of obstructive sleep apnea in Parkinson’s disease patients and controls. The Conclusion also reports that this meta-analysis found a lower risk in patients, supporting the narrower claim that not all studies found an increased prevalence. Page numbers were not provided in our copy. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Erectile dysfunction is common in males (Sakakibara et al. 2011).”
What the sources say
- Supportedcites Sakakibara et al. 2011 source
Section 4.3.1, “Male Sexual Symptoms,” reports that 79% of the men with Parkinson’s disease in a cited study had decreased erection, significantly more than healthy male controls. This supports the statement that erectile dysfunction is common in men with Parkinson’s disease. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study showed that visual component was lacking in 10% of cases (Papapetropoulos and Heather Katzen 2008).”
What the sources say
- Partly supportedcites Papapetropoulos and Heather Katzen 2008 sourceExperimental — accuracy not yet measured
The Discussion reports that seven of 70 Parkinson’s disease patients had hallucinations lacking a visual component, giving an overall prevalence of 10%. But the Results (Characteristics of hallucinators) state that those seven were 22.5% of the 31 patients who had hallucinations. Thus 10% applies to all patients studied, not to cases of hallucinations. (LLM, conf=0.92)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Progression of the dementia shows a correlation with spread of the neuropathological changes to cortical brain structures (Irwin et al. 2012).”
What the sources say
- Partly supportedcites Irwin et al. 2012 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes a proposed spread of Lewy body and neurite pathology from the brainstem to the cerebral cortex. The Results and Discussion (pages unavailable) associate greater cortical pathology with dementia in Parkinson’s disease, but do not establish that progression of dementia itself correlates with the spread over time. (LLM, conf=0.83)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
In the paper
“This may rarely be a prediagnostic symptom in PD (Tolosa and Compta 2006)”
What the sources say
- Not checked — no full text of the sourcecites Tolosa and Compta 2006 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In young onset familial PD, dystonia typically involves the foot with cramp-like discomfort or inversion of the affected foot (Tolosa and Compta 2006).”
What the sources say
- Not checked — no full text of the sourcecites Tolosa and Compta 2006 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In the majority of cases, the PD symptoms appear within 10 years from onset of the dystonia.”
What the sources say
- Not checked — no full text of the sourcecites Tolosa and Compta 2006 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In PD, the blood pressure drop may last several minutes (Jost 2003).”
What the sources say
- Not checked — no full text of the sourcecites Jost 2003 source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 15
- It may state two separate claims as one. 32
Every source the paper cites for this claim was checked and supports it.
In the paper
“The prevalence increases with advancing age both for men and women with no decreases at higher ages (De Rijk et al. 1997).”
What the sources say
- Supportedcites De Rijk et al. 1997 source
The AGE section explicitly states that Parkinson's disease prevalence increased with age in all five surveys for both men and women, with no decrease at higher ages. The claim matches that finding. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Around 80% have limb tremor, most commonly a resting pill-rolling type of tremor of the hands.”
What the sources say
- Supportedcites Jankovic 2008 source
The Tremor section (page not supplied) reports that 75% of patients had tremor during the course of Parkinson’s disease, consistent with “around 80%.” It describes the tremor as almost always prominent in an extremity and hand rest tremor as pill-rolling. (LLM, conf=0.86)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Occasionally, the tremor involves the legs and other tremor types may occur (Reichmann 2010).”
What the sources say
- Supportedcites Reichmann 2010 source
The Tremor section (page not provided) says tremor can spread to a lower limb or begin there. It also says that although resting tremor is typical of Parkinson’s disease, action tremor occurs in many patients. (LLM, conf=0.94)
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Sleep studies have shown that patients have more shallow sleep and tendency to frequent awakenings in the night (Yong et al. 2011).”
What the sources say
- Supportedcites Yong et al. 2011 source
The Discussion reports increased stage 1 sleep in Parkinson’s disease patients compared with controls, supporting the description of lighter sleep. The Results (Subjective sleep related complaints) report significantly more difficulty staying asleep and frequent awakenings among patients. These awakenings were self-reported; the study did not find an increased PSG arousal index. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
In the paper
“The prevalence of PD in industrialised countries is generally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (De Lau and Breteler 2006).”
What the sources say
- Not checked — no full text of the sourcecites De Lau and Breteler 2006 source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“It is the second most common neurodegenerative disease worldwide with incidence and prevalence on the rise along with changing population demographics (Pringsheim et al. 2014).”
What the sources say
- Not checked — no full text of the sourcecites Pringsheim et al. 2014 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The prevalence of PD in industrialised countries is generally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (De Lau and Breteler 2006).”
What the sources say
- Not checked — no full text of the sourcecites De Lau and Breteler 2006 source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Autonomic dysfunction may present prior to the diagnosis or become apparent with disease progression or be induced by medication (Koike and Takahashi 1997).”
What the sources say
- Not matchedcites Koike and Takahashi 1997
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“All areas of autonomic function may be affected and this has been reported to affect daily life of over 50% of patients (Jost 2003).”
What the sources say
- Not checked — no full text of the sourcecites Jost 2003 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“In Europe, the prevalence at ages 85-89 has been reported as 3.5% (Clarke and Moore 2007).”
What the sources say
- Not matchedcites Clarke and Moore 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
In the paper
“swallowing problems have been reported in 40-80% (Kalf et al. 2011)”
What the sources say
- Not matchedcites Kalf et al. 2011
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
In the paper
“These deformities include abnormally flexed body posture with flexion originating in the thoracic or lumbar spine (camptocormia), forward flexion of the head and neck (antecollis) and scoliosis of the spine, i.e., a lateral curve of the spine usually combined with rotation of the vertebrae (Doherty et al. 2011).”
What the sources say
- Not checked — no full text of the sourcecites Doherty et al. 2011 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In reports by Poewe and colleagues, the most frequent site for off dystonia is the foot, whereas in peak dose dystonia neck and face are more commonly involved (Poewe and Lees 1987;Poewe et al. 1988).”
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In medically treated PD, dystonia, along with dyskinesias, constitutes one of the main motor complications related to chronic therapy, usually occurring as an off-period phenomenon, but can present as peak dose dystonia or diphasic dystonia (Tolosa and Compta 2006).”
What the sources say
- Not checked — no full text of the sourcecites Tolosa and Compta 2006 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“but slow-transit constipation is by far the most common, occurring in 70-80% (Jost and Eckardt 2003;Jost 2010).”
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Salivary secretion appears to be reduced in PD despite frequent problem with dribbling of saliva in advanced disease (Cersosimo et al. 2009).”
What the sources say
- Not checked — no full text of the sourcecites Cersosimo et al. 2009 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“They last from seconds to minutes, and may recur over the day (Holroyd et al. 2001).”
What the sources say
- Not matchedcites Holroyd et al. 2001
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“Minor visual phenomena such as sense of presence and visual illusions affect 17-72% of patients and delusions about 5% (Fenelon and Alves 2010).”
What the sources say
- Not checked — no full text of the sourcecites Fenelon and Alves 2010 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The earliest symptoms include problems with executive function, i.e., planning and organizing goal-directed behaviour, but visuospatial dysfunction, impaired speech fluency and memory impairment are also observed (Williams-Gray et al. 2006).”
What the sources say
- Not checked — no full text of the sourcecites Williams-Gray et al. 2006 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Cognitive deterioration and dementia is common in PD and may occur early or late (Williams-Gray et al. 2006, 2007).”
What the sources say
- Not matchedcites Williams-Gray et al. 2006, 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“Seborrhoeic keratosis is a dermatological facial and scalp disorder that has been reported in 18.6% of patients (Fischer et al. 2001).”
What the sources say
- Not checked — no full text of the sourcecites Fischer et al. 2001 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Frequent nocturia is reported by 60% of patients and is caused by detrusor overactivity (Yeo et al. 2012).”
What the sources say
- Not checked — no full text of the sourcecites Yeo et al. 2012 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The frequency in clinically manifested PD has been reported as 27-32% (Monderer and Thorpy 2009), but symptoms may appear years or decades before the motor symptoms appear (Hickey et al. 2007).”
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Excessive daytime sleepiness has been estimated to occur in up to 50% (Monderer and Thorpy 2009) and may be partly induced by the dopaminergic drugs (Knie et al. 2011).”
What the sources say
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Visual hallucinations and illusions are common in PD and reportedly occur in a third to 40% of patients (Onofrj et al. 2007).”
What the sources say
- Not checked — no full text of the sourcecites Onofrj et al. 2007 source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“They appear to be related to the dopaminergic treatment load and possibly more to dopamine receptor agonist drugs than others (O'Sullivan et al. 2009;Ceravolo et al. 2010).”
What the sources say
- Not matchedcites O'Sullivan et al. 2009
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Ceravolo et al. 2010 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“If psychosis occurs it is usually late in the disease process in patients on high doses of drugs or may be associated with old age, cognitive impairment and history of depression (Thanvi et al. 2005).”
What the sources say
- Not checked — no full text of the sourcecites Thanvi et al. 2005 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Higher load of dopaminergic treatment may be related to the hallucinations, but disease severity, cognitive impairment, depression, older age and worse visual acuity may also be important (Holroyd et al. 2001;Fenelon and Alves 2010).”
What the sources say
- Not matchedcites Holroyd et al. 2001
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Fenelon and Alves 2010 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“This may be associated with dyskinesias or low blood concentrations of the dopaminergic drugs but does not appear to correlate with duration of the disease (Hirayama 2006).”
What the sources say
- Not checked — no full text of the sourcecites Hirayama 2006 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A meta-analysis reported that one third of patients have clinically significant depression, while a major depressive disorder was reported in 17% (Reijnders et al. 2008).”
What the sources say
- Not checked — no full text of the sourcecites Reijnders et al. 2008 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Mild cognitive impairment has been reported to be twice as common in PD as in people not affected by the disease (Aarsland et al. 2009).”
What the sources say
- Not checked — no full text of the sourcecites Aarsland et al. 2009 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“It is the second most common neurodegenerative disease worldwide with incidence and prevalence on the rise along with changing population demographics (Pringsheim et al. 2014).”
What the sources say
- Not checked — no full text of the sourcecites Pringsheim et al. 2014 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The disease has distinctive neuropathological brain changes.There is formation of abnormal proteinaceous spherical bodies called Lewy bodies (Fig. 1), and a spindleor thread-like and, in part, branching Lewy neurites in the somata of the involved nerve cells, beginning at defined induction sites and advancing in a topographically predictable sequence within the nervous system (Braak et al. 2004).”
What the sources say
- Not checked — no full text of the sourcecites Braak et al. 2004 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Relative risk of death compared with matched control populations has been reported 1.6-3.0(Clarke and Moore 2007).”
What the sources say
- Not matchedcites Clarke and Moore 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
In the paper
“Early in the course of the disease, symptoms are usually unilateral and mild and the response to treatment is fair or excellent with no variability in motor function over the day.”
What the sources say
- Not matchedcites Poewe 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“Gait and balance disturbances and speech and swallowing difficulties may appear that are poorly responding to treatment.”
What the sources say
- Not matchedcites Poewe 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“Musculoskeletal pain is reported by almost half of the patients, but such pain is common in this age group and may not always be related to the PD.”
What the sources say
- Not checked — no full text of the sourcecites Broen et al. 2012 source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Patients with PD have greater and earlier need for nursing home placements (Parashos et al. 2002), higher rates of emergency hospital admissions, longer admissions and higher in-hospital mortality than comparable general population (Low et al. 2015).”
What the sources say
- Not checked — no full text of the sourcecites Low et al. 2015 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, as I review, PD is a much more complex disease than just the motor manifestations.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
In the paper
“With progression of the disease, treatment becomes heavier and drug response less reliable and the anti-parkinsonian drugs induce potentially disabling dyskinesias.”
What the sources say
- Not matchedcites Poewe 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It remains a debilitating disorder for which no effective disease modification therapies have yet been identified.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It remains a debilitating disorder for which no effective disease modification therapies have yet been identified.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
In the paper
“Although symptoms progress and motor symptoms appear in the contralateral side, drug response is usually reliable and patients are functioning well.”
What the sources say
- Not matchedcites Poewe 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“Early in the course of the disease, symptoms are usually unilateral and mild and the response to treatment is fair or excellent with no variability in motor function over the day.”
What the sources say
- Not matchedcites Poewe 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
The paper relies on this without support.
Parkinson's disease is usually diagnosed by the first motor symptoms.
“The disease is usually diagnosed by the first motor symptoms.”
The paper relies on this without support.
Postural deformities are a frequent complication of Parkinson's disease.
“Postural deformities are a frequent complication of Parkinson's disease.”
The paper relies on this without support.
The pathophysiology of postural deformities in Parkinson's disease may be multifactorial and probably includes rigidity, axial dystonia, myopathy and centrally impaired proprioception.
“The pathophysiology of these deformities may be multifactorial and probably includes rigidity, axial dystonia, myopathy and centrally impaired proprioception.”
The paper relies on this without support.
In one study of 109 recently diagnosed Parkinson's disease patients not yet started treatment, symptoms such as apathy, excessive daytime sleepiness, sleep problems and constipation may occur in up to 60-70% prior to diagnosis and were more common than in normal controls.
“One study of 109 recently diagnosed patients who had not yet started treatment showed that symptoms such as a lack of emotional involvement and interest (apathy), excessive daytime sleepiness, sleep problems and constipation may occur in up to 60-70% of patients prior to the diagnosis and these symptoms were more common than in normal controls.”
The paper relies on this without support.
With advancing disease, non-motor symptoms generally become more troublesome for patients than motor symptoms in Parkinson's disease.
“With advancing disease, the non-motor symptoms generally become more troublesome for the patients than the motor symptoms.”
The paper relies on this without support.
Orthostatic hypotension affects 30-40% of Parkinson's disease patients.
“Orthostatic hypotension affects 30-40% of patients.”
The paper relies on this without support.
Anxiety and depression in Parkinson's disease may disappear with dopaminergic treatment, but may be persistent or recur in the long clinical course of the disease.
“Anxiety and depression may disappear with dopaminergic treatment, but may be persistent or recur in the long clinical course of the disease.”
The paper relies on this without support.
The aetiology of Parkinson's disease is probably multifactorial and there is no available treatment that will halt or stop progression of the disease.
“The aetiology of PD is probably multifactorial and there is no available treatment that will halt or stop progression of the disease.”
The paper relies on this without support.
Levodopa is standard and the most common initial therapy for Parkinson's disease patients.
“Levodopa, a prodrug to dopamine, is standard and the most common initial therapy for patients.”
The paper relies on this without support.
Early on, response to levodopa is usually good in Parkinson's disease.
“Early on, response is usually good.”
The paper relies on this without support.
With disease progression, the majority of Parkinson's disease patients experience shorter duration of response to individual doses (wearing-off), on-off symptoms, dyskinesias and other motor complications.
“With disease progression and less capacity of the system to store dopamine, the majority of patients experience shorter duration of response to individual doses (wearing-off symptoms), alternative phases with good and poor response to medication (on-off symptoms), involuntary movements of the head, trunk or limbs (dyskinesias) and other motor complications.”
The paper relies on this without support.
Parkinson's disease is a progressive multi-system neurodegenerative disease affecting people mainly in later years of life.
“Parkinson's disease (PD) is a progressive multi-system neurodegenerative disease affecting people mainly in later years of life.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Parkinson’s disease (PD) is a neurodegenerative disease in elderly caused by degeneration of dopaminergic neurons mainly in the substantia nigra pars compacta (SNc), a region of the midbrain (Sveinbjornsdottir, 2016; Alizadeh et al., 2019).”
From Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease (2022) · cites this paper as Sveinbjornsdottir, 2016
Experimental — accuracy not yet measured
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · cited 1×
“The prevalence of PD in industrialised countries is generally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (De Lau and Breteler 2006).”
BackgroundInfluentialStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
Williams‐Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. (2007) · Brain · doi:10.1093/brain/awm111 · Cited by 935
Doty, R. L., Deems, D. A., & Stellar, S. (1988) · Neurology · doi:10.1212/wnl.38.8.1237 · Cited by 838
Flagged first, then by citations
1 of the 88 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1007/s00415-003-1105-z · DOI · Paper page
Cited by
Sorted by citations
Items 1,001–1,100 of 1,401
Wang, P., Dai, W., Li, H., Li, W., Wang, Y., Liu, Y., Wang, L., Ye, F., & Xu, Y. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01470-9 · Cited by 1
“Clinically, PD is primarily marked by progressive motor impairments, including rigidity, resting tremor, and freezing of gait [5, 6].”
Correlation of Retinal Thickness and Visual Features in Patients With Parkinson's Disease
Kakimoto, A., Tsukahara‐Kawamura, T., Inoue, K., et al. (2025) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.70046 · Cited by 1
Toxic Tango in Parkinson's Disease: A dance between αSyn and iron import, export and speciation
Cosson, T., Faller, P., & Pountney, D. L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106053 · Cited by 1
Golzarian, M.-J., Alikhani, A., Soleimani, S., Kazemi, H., & Yazdani, N. (2025) · Neurology Letters · doi:10.61882/nl.4.2.114 · Cited by 1
Dawn-Ojeda, A. A., Marín-Canul, J. E., Granados-Patrón, D. A., Cuevas-Carbonell, S. G., Mut-Martín, M. C., Pérez-Izquierdo, O., Santiago, G.-T., Góngora-Alfaro, J. L., & Aranda-González, I. I. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.10.015 · Cited by 1
Bortolotto, J. W., Altenhofen, S., Martins, G. M. D. M., Cognato, G. D. P., Leite, C. E., Kist, L. W., Bogo, M. R., & Bonan, C. D. (2025) · Fish Physiology and Biochemistry · doi:10.1007/s10695-025-01597-6 · Cited by 1
“The heterodimerization of D 1 R with ADO A 1 receptors (A 1 R), and D 2 R with A 2 receptors (A 2 R), has provided a foundation for investigating novel therapeutic approaches for motor disorders (Casadó-Anguera et al. 2016; Ferré et al. 1997, 2016; Guidolin et al. 2020; Mori et al. 2022).”
Dominguez-Paredes, D., Kozielski, K., Ries, M. G., et al. (2025) · Brain Mechanisms · doi:10.1016/j.bramec.2025.202523 · Cited by 1
Rafti, D., Uzun, A.-B., Bodeanu, L., Stanciu, L.-E., Popescu, M. N., & Iliescu, M. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217472 · Cited by 1
Franyer, L., Adrian, G. M., Oscar, B. A.-N., González, J., & Pinzón, A. M. (2025) · Bacteria · doi:10.3390/bacteria4040059 · Cited by 1
“…loss of dopaminergic neurons in the substantia nigra, driven by a combination of factors including α -synuclein aggregation, mitochondrial dysfunction, neuroinflammation, impaired protein clearance, genetic mutations (e.g., LRRK2, PINK1, PARKIN), and oxidative stress from dopamine metabolism [1].”
Shastry, K. A., & Shastry, A. (2025) · SN Computer Science · doi:10.1007/s42979-025-04500-5 · Cited by 1
Impact of aging on the central and enteric nervous system in a Parkinson’s disease mouse model
Pradeloux, S., André, M. M., Fréchette, M., Drolet, M., Fontaine-lavallée, C., Côté, M., Coulombe, K., Rieux, M., Calon, F., & Soulet, D. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1576325 · Cited by 1
“…of dopaminergic (DAergic) neurons and their projections in the nigrostriatal pathway, leading to the development of motor dysfunctions (tremors, bradykinesia, postural instability, muscle rigidity) that allow the diagnosis of PD (Klingelhoefer and Reichmann, 2015; Sveinbjornsdottir, 2016).”
Hadadi, S., Arabani, S. P., & Yamaghani, M. R. (2025) · doi:10.1109/ipria68579.2025.11263747 · Cited by 1
“The symptoms associated with the PD can be classified into primary and secondary groups based on alterations in dopamine and norepinephrine levels [7][8].”
Zhang, N., Zhao, F., Miao, T., Wang, N., Wu, J., Tan, S., Wang, X., Lihou, X., Li, Y., Li, Y., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110191 · Cited by 3
Gómez-García, J. A., Torres-Pardo, A., Trigo, C., Algaba-Vidoy, M., Navarro‐López, V., Vázquez, D. F., Molero-Mateo, P., Carratalá‐Tejada, M., Rueda, F. M., & Torricelli, D. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11252917 · Cited by 1
“Non-motor symptoms are equally de-bilitating and include apathy, excessive nighttime sleepiness, constipation, mood disturbances, depression, anxiety, urinary dysfunction, and cognitive impairment [1], [2], [3].”
Oh, S., Ko, J., Enkhbayar, D., Key, J., & Urtnasan, E. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11251823 · Cited by 1
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by dopamine deficiency in the substantia nigra [1].”
Speech Acoustic Markers Can Detect Mild Cognitive Impairment in Parkinson’s Disease
Smith, K. M., Williamson, J. R., & Quatieri, T. F. (2025) · IEEE Journal of Selected Topics in Signal Processing · doi:10.1109/jstsp.2025.3620716 · Cited by 1
Choudari, K., Singh, S., Sreelekshmi, R., & Somvanshi, P. R. (2025) · Intelligent Medicine · doi:10.1016/j.imed.2025.12.004 · Cited by 1
Smartphone-Based System for Quantifying Tremor and Freezing of Gait in Parkinson’s Disease
Armoa, G. J., Abarca, V. E., & Elías, D. A. (2025) · International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS) · doi:10.1109/iciibms66230.2025.11316764 · Cited by 1
“Among the primary motor symptoms are tremors, bradykinesia, rigidity, and Freezing of Gait (FOG) [2].”
Hunziker, S., Vogel, D., Kalt, D., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1685247 · Cited by 1
“PD-related symptoms occur when dopaminergic nerve cells in the basal ganglia, a core area of the cerebrum, show accelerated degeneration and thus loss-of-function (6).”
Vedadi, Z., Miandehi, E. E., Akbari, M., Shoeibi, A., Vedadi, D., Eslami, S., & Taherzadeh, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-36736-3 · Cited by 1
Lopes, F. B., Werner, T., Bagatin, I. A., Stark, H., & Fernandes, J. P. S. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00803 · Cited by 1
Matsushita, W., Nagaki, K., Takashi, N., Ohtera, S., Ohara, C., & Takahashi, M. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261418989 · Cited by 1
“3,4 7 In recent years, technology-assisted exercise interventions, including exergames and virtual reality, have been shown to be effective in improving motor function in individuals with PD. 8 – 12 However, most studies primarily targeted individuals with mild PD, and those with more advanced…”
InfluentialYang, S.-M., Yeoh, S.-H., Lin, M.-T., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1740256 · Cited by 1
Parkinson's Disease Classification Using EEG and a Hybrid EEGNet-LSTM Architecture
Langrodi, P. T., Khodadadi, A., Modaresi, A. S., et al. (2025) · National and International Iranian Conference on Biomedical Engineering (ICBME) · doi:10.1109/icbme68496.2025.11392473 · Cited by 1
“Emerging evidence indicates that non-motor symptoms may precede motor symptoms by more than a decade, highlighting the need for early cognitive biomarkers for diagnostic purposes [3].”
Pathophysiology and Symptoms of Parkinson's Disease in Under-Resourced Settings
Akintayo, C. O., Onyekweli, S. O., Omoruyi, G. O., Akintayo, J. O., & Akinola, A. B. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-7437-6.ch001 · Cited by 1
Modeling diseases of aging in larval zebrafish, a paradoxical yet powerful strategy
Özcan, G. G., & Rihel, J. (2026) · Genetics · doi:10.1093/genetics/iyag027 · Cited by 1
“The disease primarily affects individuals in older ages, with clinical symptoms, including tremors, bradykine-sia, and motor impairments (Sveinbjornsdottir 2016).”
AI-powered speech analysis for early prediction of Parkinson's disease:
Chauhan, R., Sharma, U., & Singh, D. (2026) · Digital Health · doi:10.1177/20552076261432053 · Cited by 2
“4,5 Despite advances in neuroscience, diagnosis continues to rely on motor symptoms that appear only after signi fi cant neurodegeneration, limiting opportunities for timely intervention.”
Wang, Y., Duan, J., Zang, L., Sun, T., Lv, H., Liu, F., & Ma, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1772172 · Cited by 1
“Approximately 10 million people worldwide are affected by PD, which primarily causes motor symptoms (bradykinesia, tremor, and rigidity), but it also includes non-motor symptoms (constipation and cutaneous manifestations) (Sveinbjornsdottir, 2016).”
Micro- and nanoplastics influences in Parkinson’s disease: lessons from human stem cell models
Muhammad, K. N., Woodlief, T., & Wu, X. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1723092 · Cited by 1
“Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunctions, including tremor, rigidity, and bradykinesia, as well as non-motor symptoms (Sveinbjornsdottir, 2016).”
Hoedt, E. C., Burns, G. L., Hedley, K. E., Waller, S. E., Sánchez, T. C., Chisholm, O., MacCallum, H., Richardson, S., Suthers, B., Pepper, E., et al. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101218 · Cited by 1
“The onset of non-motor features, such as alterations in GI function, are common in early PD(Abbott et al., 2001; Arora et al., 2025; Jost, 2010; Sveinbjornsdottir, 2016).”
Kim, M., Youm, C., Park, H., Kim, B., Choi, H., Hwang, J., & Cheon, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-45122-y · Cited by 2
“Sveinbjornsdottir 30 described marked asymmetry and axial impairment in people with early-stage PD, likely attributable to unilateral motor symptoms.”
Exploring Preferences and Priorities in Advanced Parkinson’s Disease: A Discrete Choice Experiment
Arija, P., Domingos, J., Malaty, I. A., et al. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00920-4 · Cited by 1
Chatzipaschalis, I. K., Tompris, I., Fraidakis, P., et al. (2026) · Advanced Intelligent Systems · doi:10.1002/aisy.202501384 · Cited by 1
“It manifests through a broad spectrum of motor and nonmo-tor impairments, including tremor, rigidity, and bradykinesia, as well as mood alterations, drooling, and sleep disturbances [3 – 5].”
Chu, H., Ou, Q., Cai, L., Huang, Z., Wang, H., Hu, Y., Liu, Y. L., Li, J., Gao, Y., Shen, L., et al. (2026) · Advanced Fiber Materials · doi:10.1007/s42765-026-00727-w · Cited by 1
“The primary clinical manifestations are the cardinal motor tetrad including resting tremor, rigidity, bradykinesia, and postural instability [3, 4].”
Offerdahl, J. E. V., & Mor, D. E. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1846384 · Cited by 1
“A variety of non-motor symptoms can often precede motor signs and a PD diagnosis by 10 years or more (Sveinbjornsdottir, 2016).”
Molecular Mechanisms and Potential Biomarkers of Neuropsychiatric Disorders in Parkinson’s Disease
Owecki, W., Futyma, A., Kokorniak, O., Szczech, A., Słowikowski, B. K., Poszwa, J., Szymanowicz, O., Goutor, U., Jagodziński, P. P., Kozubski, W. P., et al. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin50055 · Cited by 1
Macêdo, V. F. B., Barboza, A. M. D. M., Nogueira, Y. L. S., Machado, A. S. C., & de Oliveira, N. F. (2026) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.1198 · Cited by 1
Ratnaparkhi, M. P., Jadhav, P. D., Kakad, A., Khiste, R. H., & Dalvi, S. D. (2026) · BioNanoScience · doi:10.1007/s12668-026-02677-4 · Cited by 1
van Leeuwen, A. M., Welzel, J., D’Ascanio, I., Lang, C., Vinod, V., Görrisen, P., Geritz, J., Hansen, C., Gazit, E., Tov, S. S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348957 · Cited by 1
“The symptoms of PD can result in a gradual negative impact on an individual’s capacity to perform activities of daily living and to live independently [3,4].”
Neto, O. P., Brizzi, A. C. B., Campos, S. F., Sales, M. P., de Almeida, F. D., Pedroso, W., & Pedreiro, R. C. D. M. (2026) · Archives of Gerontology and Geriatrics Plus · doi:10.1016/j.aggp.2026.100309 · Cited by 1
Viral Vector Gene Delivery to the Brain for Treating Neurogenetic Diseases
Ramos, L., Hunter, J. E., & Wolfe, J. H. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_4 · Cited by 2
Martí, Y., Nürnberg, E., Horschitz, S., Hafner, M., Schloss, P. D., Meyer‐Lindenberg, A., & Lau, T. (2017) · Journal of Cellular Biotechnology · doi:10.3233/jcb-179007 · Cited by 1
Khazov, O. (2019) · Scholarship@Western (Western University) · Cited by 1
Hochstedler, R. (2019) · Iowa Research Online (The University of Iowa) · Cited by 1
Sun, X., Dai, L., Pan, Y., et al. (2020) · Medicine · doi:10.1097/md.0000000000020363 · Cited by 1
“1 swallowing and airway protective reflexes, as manifested by dysphagia, secretion retention, and aspiration.([1,2]) Respiratory dysfunction has been noted in PD and is attributed to impaired central control of respiratory muscles, upper airway obstruction, and laryngeal muscle atony.”
Backgroundİlkhan, G. D., Çelikhisar, H., & Kilavuz, A. (2021) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.848699 · Cited by 1
Jian, W. U., Wei, Y. U., Jianping, Z. H. U., et al. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.21.03064-3 · Cited by 1
Yakşi, E., Yaşar, M. F., Dogan, N., & Balcı, M. (2022) · Experimental Biomedical Research · doi:10.30714/j-ebr.2022275817 · Cited by 1
“movement in the arms also accompany the course of the disease [3, 4].”
BackgroundAl-Taweel, A. F., & Qasim, A. A. (2018) · Journal of Baghdad College of Dentistry · doi:10.26477/jbcd.v30i3.2527 · Cited by 1
A Parkinson’s disease diagnosis approach for nonequilibrium gait data
Wang, S. (2022) · Advances in Complex Systems · doi:10.1142/s1793962323500241 · Cited by 1
Yılmaz, N. H., Kılıç, B. B., Zirh, A. T., Aslan, A., & Hanoğlu, L. (2022) · Medical Bulletin of Haseki · doi:10.4274/haseki.galenos.2022.8225 · Cited by 1
A survey of exercise beliefs among people with Parkinson’s disease in Malaysia
Ying, A. C. K., & Vasanthi, R. K. (2022) · Physiotherapy Quarterly · doi:10.5114/pq.2021.103556 · Cited by 1
Detection of Parkinson’s Disease in Alzheimer’s Patients Utilizing Brain Imaging
Bhatia, M., Kaur, A., Bhatia, S., Mridula, & Dwivedi, P. (2022) · Traitement du signal · doi:10.18280/ts.390439 · Cited by 1
“Sveinbjornsdottir [24] inspected the remodelling of global”
Comparative Study of Machine Learning Models for Early Detection of Parkinson’s
Tahir, M. A., & Farhat, Z. (2023) · Lecture notes in electrical engineering · doi:10.1007/978-981-19-8136-4_5 · Cited by 1
Proceedings of the 18th Python in Science Conference
(2019) · Proceedings of the Python in Science Conferences · doi:10.25080/majora-7ddc1dd1-026 · Cited by 1
Association between Age Gain, Parkinsonism and Pesticides: A Public Health Problem?
Cristina-Pereira, R., Trevisan, K., da Silva, E. V., da Silva, S. F., Magri, M. P. D. F., Brunelli, L. F., & Aversi‐Ferreira, T. A. (2023) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2023/v19i3376 · Cited by 2
Yulian, Z. H. U., & Xi, C. (2023) · Rehabilitation Medicine · doi:10.3724/sp.j.1329.2023.02014 · Cited by 1
Omics Analyses in a Neural Stem Cell Model of Familial Parkinson’s Disease
Notopoulou, S., Gkekas, I., & Petrakis, S. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-31978-5_12 · Cited by 1
Survey of Parkinson's Disease Detection using Different Symptoms
Palakayala, A. R., & Kuppusamy, P. (2022) · doi:10.1109/acm57404.2022.00020 · Cited by 1
Purinergic Signaling and its Role in the Stem Cell Differentiation
Zaib, S., Areeba, & Khan, I. A. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575261206231003151416 · Cited by 1
Parkinson Hastalarında Yaşam Kalitesi Hemşire ve Bakım Vericilerin Rolleri
Sen, A. K., Azizoğlu, F., & İLHAN, S. E. (2023) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.1324662 · Cited by 1
An individualized tractography pipeline for the nucleus basalis of Meynert lateral tract
Crockett, R. A., Wilkins, K. B., Zeineh, M., et al. (2023) · Imaging Neuroscience · doi:10.1162/imag_a_00067 · Cited by 1
“While the cardinal motor symptoms of PD, bradykinesia, rigidity, and tremor ( Sveinbjornsdottir, 2016) can be improved by dopaminergic interventions, treatments for cognitive impairment remain scarce and ineffective.”
An Automatic Parkinson’s Disease Classification System Using Least Square Support Vector Machine
Khandelwal, P., Khatter, K., & Relan, D. (2024) · Lecture notes in electrical engineering · doi:10.1007/978-981-99-8646-0_9 · Cited by 1
Prevalência de sintomas não motores em pessoas com doença de Parkinson no Brasil
Lopes, F. G., Vargas, A. P., & Scalzo, P. L. (2024) · Revista Neurociências · doi:10.34024/rnc.2024.v32.15926 · Cited by 1
Detection and Suppression of Parkinson's Disease Tremors Using Soft Robotics
Seshadri, U. (2024) · Proceedings of IEEE Southeastcon · doi:10.1109/southeastcon52093.2024.10500156 · Cited by 1
A review on the nutraceuticals of Parkinson's disease
Vella, C., & Blundell, R. A. (2024) · Journal of Food Nutrition and Diet Science · doi:10.55976/fnds.22024124151-65 · Cited by 1
“Non-motor symptoms may precede diagnosis by up to ten years, including lethargy, sleep problems, constipation, memory issues and mood swings [6].”
BackgroundBovin, N. A. (2024) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.572 · Cited by 1
Hu, Z., Wang, W., Yang, H., et al. (2024) · Molecules · doi:10.3390/molecules29102184 · Cited by 1
“…nonmotor symptoms experienced by almost 60% of individuals suffering from Parkinson’s disease, such as autonomic dysfunction, sensory disturbances, and neuropsychiatric manifestations including hallucinations, delusions, cognitive impairment, sleep disturbances, depression, and anxiety [1,2].”
BackgroundTan, W., Liu, Q., Cen, M.-J., Leong, I. I., Pan, Z., Liao, M., & Zhuang, L. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081041 · Cited by 1
Ito, G., Tomita, T., & Utsunomiya‐Tate, N. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150199 · Cited by 1
Probiotics protect against progressive deterioration of motor functions and Parkinson's disease
Kumari, R., Makwana, M., & Hati, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00047-4 · Cited by 1
Biswas, A., Mukherjee, S., Maji, A., Manna, A., & Sarkar, S. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24aug995 · Cited by 1
Gao, F., Zhao, J., Wang, C., et al. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14082 · Cited by 1
“14,15 A previously published meta-analysis showed that BTX injections did not provide motor symptoms improvement in patients with PD. 16 However, this conclusion may have been compromised by the inclusion of numerous non-controlled studies with limited sample sizes.”
A review of gut microbiota as a therapeutic approach for Parkinson’s disease
Ghosh, D., Ghosh, S., Sharma, M., & Datta, S. (2024) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_296_24 · Cited by 2
Pan, Z., Tan, W., Ran, X., et al. (2025) · Clinical Rehabilitation · doi:10.1177/02692155241310750 · Cited by 1
“1,2 These symptoms include paraesthesia, sleep disorders, neuropsychiatric symptoms, and autonomicdysfunctions.”
Sureshkumar, A., Luong, D., Munce, S., Bayley, M. T., Kastner, M., Scandiffio, J., Lai, N., Feng, G., Oh, J., Furlan, A. D., et al. (2025) · Disability and Rehabilitation · doi:10.1080/09638288.2025.2492312 · Cited by 2
“For example, individuals living with Parkinson’s disease may also express challenges related to mobility limitations and cognitive impairments that affect their daily life [39,40].”
Malik, M., Onyema, E. M., Uddin, M., et al. (2025) · Multimedia Tools and Applications · doi:10.1007/s11042-025-20915-x · Cited by 1
Dumican, M., Reyers, T., Malczewski, A., & Thijs, Z. (2025) · International Journal of Language & Communication Disorders · doi:10.1111/1460-6984.70124 · Cited by 1
“…often the most salient symptomology of the disease, people with Parkinson’s disease (PwPD) often display speech, voice, and swallowing dysfunction, leading to dysphagia (swallowing impairment) and dysarthria (speech/voice impairment) (Poewe et al. 2017; Sveinbjornsdottir 2016; Sapir et al. 2008).”
Feature Selection and Radial Basis Function Network for Parkinson Disease Classification
Ibrahim, A. O., Hussien, W. A., Yagoop, A. M., et al. (2017) · Kurdistan Journal of Applied Research · doi:10.24017/science.2017.3.121 · Cited by 1
Belgiovine, G., Capecci, M., Ciabattoni, L., et al. (2018) · Zooming Innovation in Consumer Technologies Conference (ZINC) · doi:10.1109/zinc.2018.8448846 · Cited by 1
“The 3% of the population worldwide after the age of 60 years is affected by PD [1].”
BackgroundUpper and Lower Limbs Dyskinesia Detection for Patients with Parkinson’s Disease
Belgiovine, G., Capecci, M., Ciabattoni, L., et al. (2018) · IEEE Global Conference on Consumer Electronics (GCCE) · doi:10.1109/gcce.2018.8574646 · Cited by 1
“Parkinson’s disease (PD) is recognized as the second common neurodegenerative disorder after Alzheimer’s disease and affects 3% of the population worldwide after the age of 60 years [1].”
BackgroundLebel, K., Duval, C., Goubault, É., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.03.016 · Cited by 1
Parkinson's Classification and Feature Extraction from Diffusion Tensor Images
Sivakumar, R., & Quinn, S. P. (2019) · Proceedings of the Python in Science Conferences · doi:10.25080/majora-7ddc1dd1-00f · Cited by 1
“Currently Parkinson’s is diagnosed based on the presence of observable motor symptoms and change in symptoms in response to medications that target dopaminergic receptors such as Levodopa [sveinbjornsdottir2016].”
BackgroundKudrevatykh, A. V., & Miliukhina, I. V. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-3-94-98 · Cited by 1
Singh, P., & Varghese, P. B. (2020) · International Journal of Medical and Exercise Science · doi:10.36678/ijmaes.2020.v06i03.004 · Cited by 1
Walmsley, S., Chandley-Pascoe, D., Collins, E., & Marquez, J. L. (2020) · New Zealand Journal of Physiotherapy · doi:10.15619/nzjp/48.3.05 · Cited by 1
“All of these were common initial symptoms reported by PLWPD participants within our study as well as by other research (Sveinbjornsdottir, 2016).”
Por qué la democracia necesita del periodismo de investigación
Waisbord, S. (2001) · Hispana · Cited by 1
Is There a Better Way to Assess Parkinsonian Motor Symptoms?—Experimental and Modelling Approach
Nair, S. S., Muddapu, V. R., Sriram, M., Aditya, R., Gupta, R., & Chakravarthy, V. S. (2021) · Series in bioengineering · doi:10.1007/978-981-16-3056-9_10 · Cited by 3
Aquatic Physical Therapy in the balance and gait of people with Parkinson’s Disease: a pilot study
Christinelli, T., Ferreira, G., Iucksch, D. D., et al. (2021) · Revista Neurociências · doi:10.34024/rnc.2021.v29.11904 · Cited by 1
Zhang, D. D., & Wu, K. (2020) · Springer eBooks · doi:10.1007/978-981-32-9196-6_5 · Cited by 1
Thijs, Z., Zhang, Y., Lierde, K. M. V., et al. (2022) · Logopedics Phoniatrics Vocology · doi:10.1080/14015439.2022.2080861 · Cited by 1
“While basal ganglia dysfunction has been suggested in stuttering, SD, and PD [45,49], the changes present in PD are more gradual.”
BackgroundGhazanfar, M., Abbas, M., Rafiq, S., et al. (2022) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v5i7.390 · Cited by 1
(2022) · DHR Proceedings · doi:10.47488/dhrp.v2is2.72 · Cited by 1
Association between Serum Alpha-Synuclein Levels and Parkinson's Disease Stage
Syafrita, Y., & Susanti, R. (2022) · Global Medical & Health Communication (GMHC) · doi:10.29313/gmhc.v10i2.9271 · Cited by 1
The flavone chrysin and usage in Parkinson's disease
Murmu, A., Krishnamoorthy, A., & Sevanan, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90052-2.00044-5 · Cited by 1
Ramos, M. E., Pothineni, S., Ni, L., Bay, A. A., Prusin, T., & Hackney, M. E. (2023) · Parkinson s Disease · doi:10.1155/2023/5519646 · Cited by 1
Physiotherapy for Neurogenic Lower Urinary Tract Dysfunction: Methods and Indications
Geraerts, I. (2023) · Springer eBooks · doi:10.1007/978-981-99-1659-7_79 · Cited by 1
Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease
Pevarello, P., & Varasi, M. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch14 · Cited by 2
Kotwani, R., Clapp, A. N., Huggins, H. E., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-223780/v1 · Cited by 1
“Hyposmia is a commonly occurring symptom of Parkinson’s Disease, reported in 80% of patients [21].”
BackgroundSigcha, L. (2021) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.68904 · Cited by 3
Metadata
- Authors
- Sveinbjornsdottir, S.
- Affiliations
- Department of Neurology Broomfield Hospital Chelmsford Essex CM1 7ET UK
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-07-11
- Volume
- 139
- Issue
- S1
- Pages
- 318-324
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2464977649
- Cited by
- 1,410
- References
- 88
- Citations by year
- 2026: 108 · 2025: 182 · 2024: 201 · 2023: 202 · 2022: 167 · 2021: 182 · 2020: 128 · 2019: 118 · 2018: 67 · 2017: 46 · 2016: 4
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, motor symptoms, non-motor symptoms, disease progression, neurodegeneration, orthostatic hypotension, constipation, sleep disorders, neuropsychiatric symptoms, autonomic dysfunction, tremor, Parkinson's disease treatment, treatment complications
- MeSH terms
- Animals, Mental Disorders, Humans, Parkinson Disease, Sleep Wake Disorders, Tremor, Disease Progression, Gait Disorders, Neurologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review